BridgeBio Receives Approval for Phase 1/2 Clinical Trial Plan of Non-Small Cell Lung Cancer Treatment Candidate in Korea

[Asia Economy Reporter Geum Bo-ryeong] Bridge Biotherapeutics announced on the 8th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1/2 clinical trial plan of the lung cancer EGFR-TKI agent BBT-176.

Bridge Bio stated, "In the case of non-small cell lung cancer, the proportion caused by activating EGFR mutations is high. Although targeted therapy (TKI) has been developed, resistance to first-generation TKIs occurs due to the T790M mutation, and the efficacy of the third-generation TKI Osimertinib rapidly decreases due to the acquired C797S mutation." They explained, "Based on preclinical results of BBT-176, clinical trials will be conducted on patients with advanced non-small cell lung cancer harboring acquired EGFR C797S triple mutations."

This content was produced with the assistance of AI translation services.